mTOR inhibitors and dyslipidemia in transplant recipients: a cause for concern?

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Mammalian target of rapamycin (mTOR) inhibitors are associated with post-transplant dyslipidemia.
• Early studies using fixed dosing without calcineurin inhibitor (CNI) reduction raised concerns.
• Modern concentration-controlled mTOR inhibitor regimens with reduced CNI exposure show a less pronounced dyslipidemic effect.

Purpose of the Study:

• To evaluate the persistent dyslipidemic effect of mTOR inhibitors in transplant recipients.
• To explore potential cardioprotective effects of mTOR inhibitors.
• To assess the clinical implications of mTOR inhibitor-associated dyslipidemia.

Main Methods:

• Review of clinical trials and experimental evidence regarding mTOR inhibitors and dyslipidemia.
• Analysis of lipid levels in kidney, liver, and heart transplant recipients.
• Examination of data on atherosclerosis progression, arterial stiffness, and ventricular remodeling.

Main Results:

• Dyslipidemia persists with mTOR inhibitors but is less pronounced in modern regimens.
• Lipid levels are typically borderline risk in kidney/liver recipients and lower in heart recipients on statins.
• mTOR inhibitors may offer cardioprotection by reducing atherosclerosis, improving arterial stiffness, and decreasing ventricular remodeling.

Conclusions:

• Post-transplant dyslipidemia with mTOR inhibitors requires monitoring and management.
• Potential cardioprotective effects of mTOR inhibitors may justify their use.
• Dyslipidemia should not be a barrier to mTOR inhibitor therapy unless unresponsive.